Securian Asset Management Inc. Has $563,000 Stake in Medpace Holdings, Inc. $MEDP

Securian Asset Management Inc. trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.2% in the second quarter, Holdings Channel reports. The institutional investor owned 1,795 shares of the company’s stock after selling 182 shares during the period. Securian Asset Management Inc.’s holdings in Medpace were worth $563,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Invesco Ltd. raised its position in shares of Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after buying an additional 102,015 shares in the last quarter. Mawer Investment Management Ltd. acquired a new stake in shares of Medpace in the first quarter valued at approximately $212,131,000. AQR Capital Management LLC raised its position in shares of Medpace by 12.4% in the first quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock valued at $158,470,000 after buying an additional 59,361 shares in the last quarter. TD Asset Management Inc raised its position in shares of Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after buying an additional 61,764 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Medpace by 36.0% in the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after buying an additional 89,347 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $605.20 on Friday. The company has a fifty day moving average of $503.13 and a 200-day moving average of $391.27. The company has a market capitalization of $17.00 billion, a PE ratio of 42.32, a price-to-earnings-growth ratio of 3.53 and a beta of 1.40. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $625.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, Director Cornelius P. Mccarthy III sold 1,662 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the transaction, the director directly owned 10,197 shares in the company, valued at approximately $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel owned 10,343 shares of the company’s stock, valued at $4,654,350. This trade represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,465 shares of company stock valued at $49,720,216 over the last three months. 20.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MEDP shares. Barclays upped their target price on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research note on Friday. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 22nd. Jefferies Financial Group raised their price objective on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Robert W. Baird set a $613.00 target price on Medpace in a research report on Friday. Finally, Truist Financial increased their target price on shares of Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $464.00.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.